vaccinee
[용어속성] Term
Immune response to SARS-CoV-2 variants of concern in vaccinated individuals
예방접종을 받은 개인에서 우려되는 SARS-CoV-2 변이체에 대한 면역 반응
Article
[키워드] African
antibodies
Antibody Response
Antibody responses
Antibody titer
Antibody titers
binding
BNT-162b2
cross-protection
detect
group
highlight
humoral
IgG antibody
IgG antibody titer
IgG titer
individual
Infection
mutant
Mutant strains
Mutation
neutralization
Neutralizing antibodies
neutralizing antibody
offered
Pfizer
RBD
RBD binding
Receptor binding domain
reduced
reduction in
robust
Saliva
saliva samples
SARS-CoV-2
SARS-CoV-2 variant
second dose
serum
South
strain
Strains
Surveillance
the antibody response
Transmission
transmission potential
uninfected
vaccinated individual
vaccinated individuals
vaccination
vaccinee
vaccinees
Vaccines
variant
variants of concern
[DOI] 10.1038/s41467-021-23473-6 PMC 바로가기 [Article Type] Article
[DOI] 10.1038/s41467-021-23473-6 PMC 바로가기 [Article Type] Article
Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines
비활성화 및 RBD-서브유닛 백신에 의해 유발된 순환 SARS-CoV-2 변이체에 대한 체액 면역 반응
Article
[키워드] (inactivated vaccine)
501Y.V2
administration
anti-RBD
antibody
antigenic
B.1.351
boost
caused
circulating SARS-CoV-2 variant
circulating SARS-CoV-2 variants
combating
Combination
comparable
conformation
Contact
convalescent
CoronaVac
Cryoelectron microscopy
disrupt
dominant
E484K
Effect
elicited
humoral immune response
Immune escape
immune response
immunology
inactivated
Inactivated vaccine
induce
K417N
leads
less
majority
mononuclear cell
mononuclear cells
Mutation
mutations
N-terminal domain
NAb
NAbs
natural infection
neutralization
neutralization activity
Neutralizing activity
Neutralizing antibodies
neutralizing antibody
NTD
Peripheral blood
Peripheral blood mononuclear cells
plasma
polar
RBD
RBD variants
receptor
Receptor-binding domain
reduced
reduction
regions
respond
SARS-CoV-2 variant
SARS-CoV-2 variants
second dose
Sequencing
single-cell
the receptor-binding domain
Tolerance
Vaccine
vaccinee
vaccinees
variants
VDJ
X-ray crystallography
ZF2001
[DOI] 10.1038/s41422-021-00514-9 PMC 바로가기 [Article Type] Article
[DOI] 10.1038/s41422-021-00514-9 PMC 바로가기 [Article Type] Article
Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants
Brief Report
[키워드] B.1.1.7
B.1.1.7 lineage
B.1.351
Brazil
Complete
elicited
enrolled
evaluated
Evidence
functional
gold standard
healthy subject
Lineage
lineages
microneutralization
mRNA BNT162b2
Neutralizing
Neutralizing antibodies
neutralizing antibody
Neutralizing antibody titer
response
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 variants
significant difference
significantly lower
South Africa
subject
Substitution
the spike protein
Transmissibility
United Kingdom
vaccination
Vaccine
vaccinee
variant
variants
VOC-202012/01
wild-type virus
Wuhan strain
[DOI] 10.3390/vaccines9050517 PMC 바로가기 [Article Type] Brief Report
[DOI] 10.3390/vaccines9050517 PMC 바로가기 [Article Type] Brief Report
Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial
무작위 시험에서 간단한 화학병 PFSPZ 백신 요법에 의한 말라리아에 대한 이종 보호
Article
[키워드] addition
administration
antibodies
antibody
approach
challenge
Chloroquine
circumsporozoite protein
complex
develop
double-blinded
Efficacy
Endpoint
Evidence
fatigue
Headaches
Heterologous
immunization
immunized
immunogenic
induce
Infection
malaria
Microarray
naïve subject
P. falciparum
participant
Phase I trials
Placebo
placebo-controlled trial
Plasmodium falciparum
Protein
purified
Pyrexia
Randomized
randomized trial
receiving
regimen
risk
Safe
tested
the vaccine
Translational research
vaccination
Vaccine
vaccinee
venous
Volunteer
[DOI] 10.1038/s41467-021-22740-w PMC 바로가기 [Article Type] Article
[DOI] 10.1038/s41467-021-22740-w PMC 바로가기 [Article Type] Article
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
Article
[키워드] abrogate
Abstract
ACE2
ACE2 binding
acute respiratory syndrome
Analysis
angiotensin-converting enzyme-2
antibody
AstraZeneca
B.1.351
binding
Brazil
changes in
convalescent
coronavirus
domain
driven by
E484K
escape
evidence of
facilitate
form
Immune escape
immunodominant
K417N
large cohort
Lineage
mAb
monoclonal antibody
Mutation
N501Y
neutralization
neutralization titer
Neutralizing
NTD
offer
P.1
Pfizer
receptor
receptor ACE2
Receptor-binding domain
reduced
reveal
SARS-CoV-2
SARS-CoV-2 isolate
SARS-CoV-2 variant
sequence
sera
serum
serum sample
serum samples
South Africa
Spike protein
structure-function
the SARS-CoV-2
vaccinated individual
Vaccine
vaccinee
variant
viral cell
viral spike protein
widespread
[DOI] 10.1016/j.cell.2021.02.037 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.cell.2021.02.037 PMC 바로가기 [Article Type] Article
Comparative Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid-Based Serological Assays
Communication
[키워드] Anti-spike
antibody
assessment
Breakthrough infection
Comparative
COVID-19
detectable
different time point
Effect
epitope
Euroimmun
expected
first dose
humoral
IgA
IgG
IgM
individual
natural infection
nucleocapsid
positive
Protein
RNA vaccine
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 spike protein
second dose
serological
serological response
serology
serum sample
specificity
Spike protein
Surveillance
the vaccine
vaccination
vaccination against COVID-19
vaccinee
while
[DOI] 10.3390/diagnostics11030426 PMC 바로가기 [Article Type] Communication
[DOI] 10.3390/diagnostics11030426 PMC 바로가기 [Article Type] Communication
COVID-19 Vaccine: A comprehensive status report
Review
[키워드] ADE, Antibody-dependent enhancement
age
angiotensin
antibodies
approach
ARDS, acute respiratory distress syndrome
benefit
China
clinical
clinical trials
co-morbid conditions
Convalescent plasma therapy
CoV, coronavirus
COVID-19
COVID-19 pandemic
COVID-19 vaccine
COVID-19 vaccine development
COVID-19, Coronavirus disease 2019
CP, convalescent plasma
curtail
DC, Dendritic Cells
DPP4, Dipeptidyl Peptidase
effective
Efficacy
effort
elicit
estimates
frontline healthcare worker
Genetic
hACE2
hACE2, Human Angiotensin- Converting Enzyme 2
Health
host cell
immunization
include
individual
involved
LAV, Live Attenuated Vaccine
limitations
LNP, Lipid Nanoparticle
MERS
MERS-CoV, Middle East respiratory syndrome coronavirus
monoclonal antibodies
monoclonal antibody
nAb, Neutralizing Antibody
Novel coronavirus
NSP, Non-structural Proteins
NTD, N Terminal Domain
outbreak
pandemic
Pathogenesis
platform
protective immunity
Protein subunit vaccines
RBD, Receptor Binding Domains
RBM, receptor binding motif
reactivity
receptor
SARS-CoV
SARS-CoV-2
SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2
SARS-CoV, severe acute respiratory syndrome coronavirus
SARS, Severe acute respiratory syndrome
Scientific community
Spanish flu
the disease
TLR, Toll-like receptor
TMPRSS2, Transmembrane Protease Serine 2
Vaccination strategy
Vaccine
Vaccine development
vaccinee
Vaccines
virus
VLP, virus-like particle
WHO
[DOI] 10.1016/j.virusres.2020.198114 PMC 바로가기 [Article Type] Review
[DOI] 10.1016/j.virusres.2020.198114 PMC 바로가기 [Article Type] Review